MNG1172
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.607
- INFLAMMATORY_RESPONSE+0.452
- IL6_JAK_STAT3_SIGNALING+0.438
- TGF_BETA_SIGNALING+0.438
- PROTEIN_SECRETION+0.422
- ANDROGEN_RESPONSE+0.402
- APOPTOSIS+0.394
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.377
- KRAS_SIGNALING_UP+0.376
- HYPOXIA+0.373
Top 10 suppressed
- MYC_TARGETS_V2-0.542
- DNA_REPAIR-0.330
- WNT_BETA_CATENIN_SIGNALING-0.328
- OXIDATIVE_PHOSPHORYLATION-0.312
- MYC_TARGETS_V1-0.300
- E2F_TARGETS-0.197
- UNFOLDED_PROTEIN_RESPONSE-0.057
- ADIPOGENESIS-0.005
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.015
- FATTY_ACID_METABOLISM+0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_593HEWBF | Ganglioglioma | — | 0.905 |
| 2 | MNG19 | — | — | 0.891 |
| 3 | SRR10900576 | — | — | 0.887 |
| 4 | ERR2598110 | fetal | fetal | 0.883 |
| 5 | BS_52426AMF | low-grade glioma | — | 0.882 |
| 6 | BS_QRNSKFMS | pilocytic astrocytoma | — | 0.874 |
| 7 | 59627_S122 | — | cohortA4 | 0.873 |
| 8 | MNG856 | — | — | 0.871 |
| 9 | TCGA-DK-A1AF-01A-11R-A13Y-07 | — | — | 0.868 |
| 10 | SRR27320658 | — | — | 0.867 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.607 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.452 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.438 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.438 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.422 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.402 | Inavolisib | — uncovered |
| APOPTOSIS | 0.394 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.377 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.376 | Inavolisib | — uncovered |
| HYPOXIA | 0.373 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.370 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.357 | Idelalisib | — uncovered |
| COMPLEMENT | 0.335 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.326 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.317 | Idelalisib | — uncovered |
| COAGULATION | 0.312 | Binimetinib | — uncovered |
| UV_RESPONSE_DN | 0.311 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.309 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.308 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.279 | Remibrutinib | — uncovered |